Ten Questions Screen Helps ID Disability in HIV+ Children

Share this content:
Ten Questions Screen Helps ID Disability in HIV+ Children
Ten Questions Screen Helps ID Disability in HIV+ Children

THURSDAY, July 19, 2018 (HealthDay News) -- The Ten Questions (TQ) screen is an effective way to screen HIV-positive children for neurodevelopmental problems in resource-poor areas, according to a study published online July 3 in PLOS ONE.

Justin Knox, M.P.H., from Columbia University in New York City, and colleagues assess the ability of the TQ screen to identify developmental disability among HIV-positive and HIV-negative children living in South Africa. Participants included 1,330 4-to-6-year-old children and 1,231 of their caregivers.

The researchers found that there was a high prevalence of disability in the sample. HIV-positive children were more likely to screen positive on at least one TQ item (59.3 versus 42.8 percent; P = 0.01), be delayed in sitting, standing or walking (odds ratio [OR], 3.89) and have difficulty walking or weakness in the arms or legs (OR, 2.7), compared to HIV-negative children. HIV-positive children were more likely to be diagnosed, through a doctor's assessment, with gross motor disability (OR, 3.5) and hearing disability (OR, 2.5). HIV-positive children were also more likely to have cognitive delay (OR, 2.2) and language delay (OR, 4.3), based on independent psychological assessment. The sensitivity and specificity of the TQ for serious disability among HIV-positive children was 100 and 51.2 percent, respectively, and 90.2 and 63.9 percent, respectively, among HIV-negative children.

"In this first report of the use of the TQ screen in the isiZulu language, it was found to have high sensitivity for detecting serious developmental disabilities in children, especially HIV-positive children," the authors write.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Moves to Restrict Flavored E-Cig Sales, Ban Menthol Cigarettes

FDA Moves to Restrict Flavored E-Cig Sales, Ban ...

The move stops short of the full ban on e-cigarettes that had been expected

Name-Brand Medications Driving Spike in U.S. Drug Spending

Name-Brand Medications Driving Spike in U.S. Drug Spending

Greatest costs for Humira, Remicade, Enbrel, Novolog, and Neulasta

is free, fast, and customized just for you!




Already a member?

Sign In Now »